Dimensional Fund Advisors LP Cuts Stake in Five Prime Therapeutics, Inc. (FPRX)

Dimensional Fund Advisors LP lessened its position in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 4.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 889,576 shares of the biotechnology company’s stock after selling 43,834 shares during the quarter. Dimensional Fund Advisors LP owned approximately 3.19% of Five Prime Therapeutics worth $26,787,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in FPRX. American International Group Inc. raised its stake in shares of Five Prime Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 16,614 shares of the biotechnology company’s stock worth $601,000 after buying an additional 1,100 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Five Prime Therapeutics by 1.2% during the 1st quarter. Teachers Advisors LLC now owns 241,371 shares of the biotechnology company’s stock worth $8,726,000 after buying an additional 2,943 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Five Prime Therapeutics by 39.2% during the 1st quarter. Legal & General Group Plc now owns 9,168 shares of the biotechnology company’s stock worth $331,000 after buying an additional 2,583 shares during the last quarter. Morgan Stanley raised its stake in shares of Five Prime Therapeutics by 12.7% during the 1st quarter. Morgan Stanley now owns 121,684 shares of the biotechnology company’s stock worth $4,399,000 after buying an additional 13,750 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Five Prime Therapeutics during the 1st quarter worth $16,734,000. 84.01% of the stock is owned by institutional investors and hedge funds.

Shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) opened at $45.05 on Friday.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.43). Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The business had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.32 million. During the same quarter in the prior year, the firm posted ($0.49) earnings per share. The firm’s quarterly revenue was down 16.1% on a year-over-year basis. research analysts forecast that Five Prime Therapeutics, Inc. will post -5.5 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/04/dimensional-fund-advisors-lp-cuts-stake-in-five-prime-therapeutics-inc-fprx.html.

In other news, Director William R. Ringo sold 600 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $45.33, for a total transaction of $27,198.00. Following the completion of the transaction, the director now directly owns 600 shares in the company, valued at approximately $27,198. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William R. Ringo sold 1,800 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $40.26, for a total transaction of $72,468.00. Following the transaction, the director now owns 1,200 shares of the company’s stock, valued at $48,312. The disclosure for this sale can be found here. Insiders sold a total of 4,400 shares of company stock valued at $175,666 over the last quarter. 6.50% of the stock is owned by company insiders.

Several research firms have recently issued reports on FPRX. Royal Bank Of Canada reaffirmed a “buy” rating and set a $41.00 price target on shares of Five Prime Therapeutics in a research note on Wednesday, October 25th. Zacks Investment Research raised Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price target for the company in a research note on Monday, October 16th. BMO Capital Markets raised Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, October 16th. Jefferies Group LLC reaffirmed a “buy” rating and set a $52.00 price target on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. Finally, ValuEngine raised shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $54.83.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

What are top analysts saying about Five Prime Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Five Prime Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit